Amdocs
DOX
$62.43
-1.75%
Amdocs Limited is a global provider of software and services to communications, entertainment, and media service providers, offering a broad portfolio of open and modular cloud solutions spanning digital business systems, legacy business and operational support systems (BSS/OSS), and AI-driven network automation across wireless, broadband, cable, fiber, and satellite verticals. The company occupies a deeply entrenched, mission-critical position in the telecom IT stack, functioning as a sticky, high-switching-cost incumbent vendor rather than a disruptive challenger, with the majority of revenue derived from long-term managed services and licensing arrangements concentrated in North America. The current investor narrative is dominated by the tension between Amdocs' defensive, cash-generative business model and a pronounced de-rating: shares have fallen sharply over the past year as telecom carrier capex restraint, delayed 5G monetization spending, and sluggish revenue growth (just 2.66% year-over-year in the most recent quarter) have weighed on sentiment. Management's push to reposition the portfolio around AI-enabled digital transformation and cloud-native offerings is the central bull case, but the market is clearly debating whether these initiatives can offset a maturing core and whether the recent margin volatility — including a notable earnings dip in the June 2026 quarter — signals structural pressure or merely timing noise.…
DOX
Amdocs
$62.43
Investment Opinion: Should I buy DOX Today?
We assign a Hold rating on Amdocs, balancing its deep value and strong cash flow against stagnant growth and earnings volatility. The analyst consensus average target price of $79.25 implies 34.7% upside, but with only 4 analysts and no standardized recommendation, conviction is low. The core thesis is that the stock is a cash cow with a 7% free cash flow yield and a 2.46% dividend yield, but it lacks a near-term catalyst to reaccelerate growth above the low single digits.
The supporting evidence for a Hold is compelling: the forward PE of 7.33x is exceptionally low, the PEG ratio of 0.85 suggests undervaluation relative to growth, and the EV/EBITDA of 10.38x is reasonable for a mature software company. Revenue growth of 2.66% is weak, but profitability remains solid with an operating margin of 18.16% and ROE of 16.47%. Free cash flow of $638.8 million comfortably covers the dividend and buybacks, and the debt-to-equity of 0.24 provides financial stability. However, the recent earnings dip and the multi-year de-rating from a PS above 8x to 2.01x indicate that the market has repriced the stock for a low-growth future.
The biggest risks that could invalidate the Hold rating are a further deceleration in revenue growth below 2%, a sustained decline in operating margins below 15%, or the loss of a major customer. The rating would upgrade to Buy if revenue growth accelerates above 5% or if the forward PE remains below 10x with improving earnings visibility. It would downgrade to Sell if revenue contracts or if free cash flow declines significantly. Relative to its history and peers, Amdocs appears undervalued on a price-to-sales basis, but the low growth rate justifies a discount. The stock is fairly valued at current levels, with limited downside but also limited upside until growth inflects.
Sign up to view all
DOX 12-Month Price Forecast
Amdocs presents a classic value trap dilemma: it is statistically cheap with a forward PE of 7.33x and a 7% free cash flow yield, but its growth is stagnant and earnings are volatile. The low beta of 0.45 and defensive characteristics make it suitable for risk-averse investors, but the lack of a near-term catalyst limits upside. The base case (55% probability) sees the stock trading in the $65-$80 range as it slowly recovers, while the bear case (20%) risks a break below $50. We would upgrade to bullish if revenue growth accelerates above 5% or if the company demonstrates sustained margin stability; we would downgrade to bearish if revenue contracts or if free cash flow deteriorates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Amdocs's 12-month outlook, with a consensus price target around $79.25 and implied upside of +26.9% versus the current price.
Average Target
$79.25
6 analysts
Implied Upside
+26.9%
vs. current price
Analyst Count
6
covering this stock
Price Range
$63 - $105
Analyst target range
Analyst coverage of Amdocs is thin, with only 4 analysts contributing to the consensus, which is typical for a mid-cap ($9.1 billion market cap) enterprise software name with limited institutional buzz. The consensus average target price is $79.25, implying +34.7% upside from the current price of $58.84 — a substantial premium that suggests the analyst community views the recent selloff as overdone. However, the recommendation field is listed as "none," indicating no standardized consensus rating is available, and the institutional ratings history shows a mix of Buy/Overweight ratings (Stifel, Barclays, B of A, Oppenheimer, Citigroup) alongside a notable downgrade by Wolfe Research from Outperform to Peer Perform in November 2025. The overall tone leans cautiously bullish, but the lack of a formal consensus recommendation and the small analyst count temper conviction.
The target price range is extremely wide, from a low of $63.00 to a high of $105.00 — a spread of $42.00, or 67% of the low target — which signals high uncertainty and divergent views on the company's trajectory. The low target of $63.00 implies just +7.1% upside and likely assumes continued low-single-digit growth, stable margins, and no multiple re-rating, essentially a "value with limited catalyst" scenario. The high target of $105.00 implies +78.4% upside and would require either significant multiple expansion (back toward historical PS/PE norms), an acceleration in AI/cloud-driven revenue, or a major new contract win cycle. The wide dispersion, combined with the recent Wolfe downgrade and the absence of any recent upgrades, suggests the analyst community is divided and awaiting clearer evidence of a growth inflection before raising targets. Investors should note that with only 4 analysts, the consensus is statistically fragile and individual analyst revisions can swing the average materially.
Drowning in data?
Find the real signal!
Bulls vs Bears: DOX Investment Factors
The bear case currently has stronger evidence, primarily due to the company's stagnant revenue growth of 2.66% and severe earnings volatility, which have driven a multi-year de-rating. However, the bull case is supported by deep value metrics, including a forward PE of 7.33x and a 7% free cash flow yield, suggesting that much of the pessimism is already priced in. The single most important tension is whether Amdocs' AI and cloud transformation initiatives can reaccelerate growth before the core business deteriorates further; if they succeed, the stock could re-rate significantly, but if they fail, the low multiple could prove justified. The low beta and defensive characteristics provide some downside protection, but the lack of a clear growth catalyst keeps the risk/reward balanced at current levels.
Bullish
- Deep Value on Forward Earnings: The forward PE of 7.33x is extraordinarily low for a profitable software infrastructure company, implying the market is pricing in a severe earnings decline that may not materialize. With consensus EPS estimates of $11.23, the stock trades at a fraction of the broader software sector's multiple, offering substantial upside if earnings merely meet expectations.
- Strong Free Cash Flow Generation: Amdocs generated $638.8 million in trailing free cash flow, a 7.0% FCF yield on its $9.12 billion market cap. The most recent quarter converted 87% of operating cash flow into FCF, funding $142.6 million in buybacks and $60.4 million in dividends without straining the balance sheet.
- Conservative Balance Sheet and Dividend: Debt-to-equity of 0.24 and a current ratio of 1.17 provide financial flexibility, while the 2.46% dividend yield with a 39.7% payout ratio is well-covered and offers a valuation floor. This is a rare combination in the software sector, where many peers carry higher leverage or pay no dividend.
- Analyst Targets Imply Significant Upside: The consensus average target price of $79.25 represents 34.7% upside from the current $58.84, with a high target of $105.00 implying 78.4% upside. Even the low target of $63.00 suggests 7.1% upside, indicating that analysts see limited downside from current levels.
Bearish
- Stagnant Revenue Growth: Revenue grew just 2.66% year-over-year in the most recent quarter to $1.175 billion, with sequential growth under 1% per quarter. This is roughly one-quarter the pace of the broader technology sector and reflects a maturing core business tethered to subdued telecom capex cycles.
- Severe Earnings Volatility: Net income collapsed to $62.17 million in Q3 2026 from $137.8 million in Q2 2026, a 55% sequential decline, driven by a $120.5 million swing in other income/expenses. This earnings instability raises questions about the reliability of forward estimates and the company's ability to meet consensus.
- Multi-Year Multiple Compression: The PE ratio has fallen from over 29x in Q4 2024 to 16.15x today, while the PS ratio has collapsed from above 8x in 2023–2024 to just 2.01x. This sustained de-rating suggests the market has permanently repriced the stock for lower growth, and a re-rating may not occur without a clear growth catalyst.
- Telecom Sector Concentration Risk: Amdocs derives the majority of its revenue from North American communications and media service providers, exposing it to the capital spending cycles of a small number of large customers. With telecom carriers restraining capex and delaying 5G monetization investments, this concentration is a persistent headwind.
DOX Technical Analysis
Amdocs is in a clear, sustained downtrend on a trailing twelve-month basis, with the stock down 28.07% over the past year and 26.60% year-to-date, a stark underperformance versus the S&P 500's +16.0% and +14.17% respective gains. At the current price of $58.84, the stock sits at roughly 24.6% of its 52-week range (calculated as ($58.84 − $49.74) / ($85.63 − $49.74)), placing it in the lower quartile of its annual band and just 18.3% above the 52-week low of $49.74. This positioning is characteristic of a stock in a confirmed downtrend rather than a value opportunity, though the proximity to the low also means downside is technically bounded by a well-defined floor that has already been tested. The maximum drawdown of −42.01% underscores the severity of the de-rating and the absence of meaningful dip-buying support until the $50 area.
Short-term momentum presents a nuanced picture: the 1-month change of −1.62% and 3-month change of +13.35% reveal a stock that has staged a meaningful recovery off its June lows near $49.87 but has stalled in recent weeks. The 3-month gain of 13.35% actually outpaces the S&P 500's +3.13% over the same period, producing a positive relative strength of +10.22 over three months — a notable divergence from the deeply negative 1-year relative strength of −44.07. This suggests the stock may be in the early innings of a mean-reversion rally, but the recent 1-month stall (−1.62% vs. SPY's +2.12%, a −3.74% relative drag) indicates the recovery has lost momentum and is consolidating. The 6-month change of −6.60% versus SPY's +14.59% (relative strength −21.19) confirms that the intermediate-term trend remains negative despite the recent bounce.
Key technical levels are well-defined: support rests at the 52-week low of $49.74, which coincides with the June 2026 trough of $49.87, forming a double-bottom-like base that would signal capitulation if broken. Resistance sits at the 52-week high of $85.63, though a more immediate ceiling exists in the $63–$65 zone where the stock repeatedly failed in August and September 2026. A breakout above $65 would be the first meaningful higher-high signal and could open a path toward the mid-$70s, while a breakdown below $49.74 would likely trigger momentum-driven selling toward uncharted territory. The beta of 0.45 is a critical risk-management input: Amdocs is roughly 55% less volatile than the broader market, meaning its −28% annual decline occurred with far less market beta than a typical high-beta name, implying company-specific (idiosyncratic) headwinds rather than macro-driven selling — and conversely, that any recovery will likely be gradual rather than explosive.
Beta
0.41
0.41x market volatility
Max Drawdown
-41.7%
Largest decline past year
52-Week Range
$50-$86
Price range past year
Annual Return
-25.8%
Cumulative gain past year
| Period | DOX Return | S&P 500 |
|---|---|---|
| 1m | +7.4% | -2.0% |
| 3m | +12.9% | -2.0% |
| 6m | -4.2% | +3.1% |
| 1y | -25.8% | +10.4% |
| ytd | -22.1% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOX Fundamental Analysis
Amdocs' revenue trajectory is best characterized as stagnant-to-modestly-growing, with the most recent quarter (ending June 30, 2026) delivering $1.175 billion in revenue, up just 2.66% year-over-year. The multi-quarter trend reveals a concerning deceleration: revenue progressed from $1.144 billion (Q3 2025) to $1.156 billion (Q1 2026) to $1.172 billion (Q2 2026) to $1.175 billion (Q3 2026), a sequential growth rate of well under 1% per quarter. While the company operates in a single reporting segment, the geographic concentration in North America and the reliance on large carrier customers means growth is tethered to telecom capex cycles, which have been subdued. The investment case increasingly hinges on whether AI and cloud transformation spending can reaccelerate a business that is growing at roughly one-quarter the pace of the broader technology sector.
Profitability is the company's strongest fundamental attribute, though it showed notable volatility in the latest quarter. Net income in Q3 2026 was $62.17 million on $1.175 billion in revenue, yielding a net margin of just 5.29% — a sharp deterioration from the prior quarter's $137.8 million (11.76% net margin) and Q1 2026's $157.6 million (13.63% net margin). This compression was driven largely by a $120.5 million swing in total other income/expenses (versus −$15.6 million in Q2), not by operational deterioration, as operating income remained healthy at $210.96 million (17.96% operating margin). Gross margin has been remarkably stable in the 37.0%–39.8% range over the past four quarters, with the latest quarter at 39.76%, and the trailing gross margin of 36.58% and operating margin of 18.16% are consistent with a mature, high-value enterprise software business. The key question is whether the Q3 earnings dip is a one-time item or the start of margin erosion.
Balance sheet and cash flow fundamentals are solid and supportive of the investment case. The debt-to-equity ratio of just 0.24 is conservative, and the current ratio of 1.17 indicates adequate short-term liquidity, though not lavish. Free cash flow on a trailing twelve-month basis is $638.8 million, and the most recent quarter generated $171.9 million in FCF on $197.2 million in operating cash flow, a healthy 87% conversion rate. The company returned substantial capital to shareholders, repurchasing $142.6 million in stock and paying $60.4 million in dividends in Q3 alone, funded entirely from internal cash generation. With ROE of 16.47% and ROA of 8.12%, Amdocs demonstrates efficient capital deployment, and the 2.46% dividend yield with a 39.7% payout ratio leaves ample room for continued shareholder returns. The primary financial risk is not solvency but growth: with revenue expanding at ~2.7% and FCF yield of roughly 7% (based on $638.8 million FCF against a $9.12 billion market cap), the company is a cash cow in search of a growth catalyst.
Quarterly Revenue
$1.2B
2026-06
Revenue YoY Growth
+2.7%
YoY Comparison
Gross Margin
39.8%
Latest Quarter
Free Cash Flow
$638841999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOX Overvalued?
Because Amdocs is solidly profitable — with trailing net income positive and EPS of $0.59 in the latest quarter — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 16.15x and a forward PE of just 7.33x, an extraordinarily wide gap that implies the market expects a dramatic earnings inflection. This forward multiple is based on consensus estimated EPS of $11.23, which is more than 18x the trailing EPS figure of $0.06 — a discrepancy that likely reflects either a data artifact in the trailing EPS calculation or a massive expected earnings recovery. If the forward estimate is credible, the stock is priced for a profound earnings rebound; if not, the trailing PE of 16.15x is the more reliable anchor and suggests a reasonably valued, if unexciting, cash-generative business.
On a peer-relative basis, Amdocs' valuation appears mixed. The PS ratio of 2.01x and EV/Sales of 1.55x are modest for a software infrastructure company, and the PEG ratio of 0.85 (below 1.0) conventionally signals undervaluation relative to growth. However, the PB ratio of 2.66x and PCF ratio of 12.17x are less compelling, and the EV/EBITDA of 10.38x sits in the middle of the range for mature enterprise software peers. Against the broader software infrastructure sector, where premium names often command 5x–10x sales, Amdocs' 2.0x PS ratio represents a significant discount, arguably justified by its low-single-digit growth rate and telecom-sector concentration risk. The 2.46% dividend yield is a meaningful differentiator versus most software peers, many of which pay no dividend, and provides a valuation floor for income-oriented investors.
Historical context is instructive: Amdocs' PE ratio has compressed dramatically from levels above 20x in 2023 and early 2024 (e.g., 23.05x in Q4 2025, 29.55x in Q4 2024) to the current 16.15x, while the PS ratio has fallen from above 8x in 2023–2024 to just 2.01x today. This represents a multi-year de-rating that has taken the stock from premium software multiples to levels more typical of a low-growth value stock. The current PE of 16.15x is near the bottom of its multi-year range, and the PS of 2.01x is a fraction of its historical 7x–9x band. This compression suggests the market has fully repriced Amdocs for its growth challenges; the risk is that it reflects permanent structural deterioration rather than a cyclical trough, while the opportunity is that any growth reacceleration could drive significant multiple expansion back toward historical norms.
PE
16.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~25x
vs. Industry Avg
27.8x
Industry PE ~27.8x*
EV/EBITDA
10.4x
Enterprise Value Multiple
Investment Risk Disclosure
Amdocs faces financial and operational risks primarily stemming from its stagnant growth and earnings volatility. Revenue grew just 2.66% year-over-year in Q3 2026, with sequential growth under 1%, indicating a maturing core business that is heavily dependent on telecom carrier spending. The company's net margin collapsed to 5.29% in the latest quarter from 11.76% in the prior quarter, driven by a $120.5 million swing in other income/expenses, highlighting earnings instability. While the balance sheet is conservative with a debt-to-equity of 0.24 and a current ratio of 1.17, the low growth rate means the company must rely on cost controls and buybacks to drive EPS growth, which may not be sustainable if margins face structural pressure.
Market and competitive risks include the potential for further multiple compression if growth does not inflect. The stock trades at a trailing PE of 16.15x and a PS of 2.01x, which, while low relative to historical levels, could contract further if the company fails to demonstrate accelerating revenue. The telecom sector is undergoing consolidation and capex restraint, and Amdocs faces competition from larger IT services firms and niche cloud-native players. With a beta of 0.45, the stock is less sensitive to macro shocks, but its idiosyncratic risks are pronounced: the recent Wolfe Research downgrade and thin analyst coverage (only 4 analysts) increase the risk of negative surprises. Additionally, the wide target price range ($63 to $105) reflects high uncertainty about the company's trajectory.
In a worst-case scenario, a continued decline in telecom capex, coupled with a failure to gain traction in AI and cloud offerings, could lead to revenue contraction and further margin erosion. If the company misses earnings expectations and analysts downgrade the stock, the shares could retest the 52-week low of $49.74, representing a 15.5% decline from the current price of $58.84. A more severe scenario, such as a major customer loss or a broader tech selloff, could push the stock below its 52-week low toward the analyst low target of $63.00? Wait, the analyst low target is $63.00, which is above the current price, so that's not a downside scenario. Actually, the 52-week low is $49.74, and the maximum drawdown is -42.01%, so from the current price, a drop to $49.74 would be a 15.5% loss. If the stock breaks below $49.74, it could enter uncharted territory, potentially falling to $45 or lower, implying a loss of over 23% from current levels. Investors should be prepared for significant downside if the growth narrative fails to improve.
FAQ
The key risks include: 1) Financial risk: earnings volatility, with net income dropping 55% sequentially in Q3 2026 due to a $120.5 million swing in other expenses. 2) Competitive risk: reliance on telecom carriers that are restraining capex, and competition from larger IT services firms. 3) Macro risk: low beta of 0.45 reduces market sensitivity, but a telecom spending downturn could hurt revenue. 4) Company-specific risk: thin analyst coverage (4 analysts) and a wide target range ($63-$105) indicate high uncertainty. The most severe risk is a revenue decline that breaks the stock below its 52-week low of $49.74.
Our 12-month forecast has three scenarios: bull case (25% probability) targets $85-$105, assuming revenue growth accelerates above 5% and multiple expansion; base case (55%) targets $65-$80, assuming steady low-single-digit growth and stable margins; bear case (20%) targets $45-$55, assuming revenue contraction and margin erosion. The base case is most likely, with the stock gradually recovering toward the analyst average target of $79.25. The key assumption is that Amdocs maintains its free cash flow generation and dividend, while avoiding major customer losses.
DOX appears undervalued on most metrics. The forward PE of 7.33x is exceptionally low, and the PEG ratio of 0.85 is below 1.0, typically signaling undervaluation. The PS ratio of 2.01x is a fraction of its historical 7x-9x range, and the EV/EBITDA of 10.38x is reasonable for a mature software company. However, the low valuation reflects the market's skepticism about future growth, given the 2.66% revenue growth rate. If the company can reaccelerate growth, the multiple could expand significantly, but if growth remains stagnant, the discount may persist.
DOX is a good buy for value and income investors, but not for growth-oriented investors. The stock trades at a forward PE of 7.33x and offers a 2.46% dividend yield, with a 7% free cash flow yield, suggesting deep value. Analyst targets imply 34.7% upside to $79.25, but the company's revenue growth is only 2.66%, and earnings are volatile. The biggest downside risk is a break below the 52-week low of $49.74, which would represent a 15.5% loss. Therefore, it is suitable for patient investors who can tolerate low growth in exchange for stability and income.
DOX is more suitable for long-term investment due to its low beta (0.45), stable dividend (2.46% yield), and deep value characteristics. Short-term trading is less attractive given the lack of near-term catalysts and the stock's recent downtrend. The company's earnings visibility is moderate, with recurring revenue from long-term contracts, but growth is slow. A minimum holding period of 2-3 years is recommended to allow for potential multiple expansion and to capture the dividend. Investors should monitor quarterly earnings for signs of a growth inflection.